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he  compound  mutation,  a  model  for  acquire  long  QT  syndromeCongenital long QT syndrome is a relatively rare disease and
t has been reported that its incidence is 1:2000 [1].  Mutations
hat cause long QT syndrome usually alter cardiac repolarization
urrents and prolong action potential duration. Most of the patients
ave one mutation but some patients have two  or more mutations
imultaneously. From the general incidence of long QT syndrome,
he theoretical frequency of patients with compound mutations
ill be 0.05% of the patients, but the real frequency is up to 9% of
he probands [2–6]. Although the family members who  have one
f the mutations often have mild phenotype and relatively benign
linical course, probands who have compound mutations show
ore severe clinical phenotypes. Previous reports demonstrated
hat patients with compound mutations had longer QT interval
2,5,6],  younger age at onset of the cardiac event [2,5], and were
ore likely to have cardiac arrest [2,4,6] than patients with a sin-
le mutation. Indeed, a patient reported by Ito et al. had markedly
ong QT interval with bizarre T wave morphology, and experienced
borted cardiac arrest [7].
Cardiac repolarization is regulated by periodical activation and
nactivation of cardiac ion channels [8].  Inward currents by sodium
INa) and calcium ions (ICa) depolarize myocytes and outward
urrents by some potassium currents (Ito, IKr, IKs, and IK1) repolarize
yocytes to resting membrane potential. Disruption of the bal-
nce of the outward and inward currents prolongs action potential
uration and then causes QT interval prolongation. Prolongation
f the action potential duration results in calcium overload in the
yocytes and inward depolarizing current by calcium ion initi-
tes early after depolarization and triggered activity. Experimental
tudies have shown compound ion channel dysfunction promotes
ccurrence of torsades de pointes (TdP). Emori and Antzelevitch
nitially reported that the combination of the potassium current
ysfunction by IKr (LQT2 model) and IKs blockers (LQT1 model)
eproduced clinical phenotypes of acquired long QT syndrome and
his can be applied to compound mutations [9].  After this report,
thers showed that a combination of blockers of the potassium
urrents and/or enhancers of the late sodium current in experimen-
al models reproduced clinical phenotypes of compound mutations
10–12]. Although relatively low doses of a single drug alone had
ild effects on cardiac repolarization and did not initiate TdP, a
ombination of these drugs prolonged action potential duration
nd QT interval, and frequently promoted TdP. Because several ion
urrents contribute to cardiac repolarization, mild to moderate dys-
unction of an ion channel can be clinically latent. A combination
DOI of original article: http://dx.doi.org/10.1016/j.jccase.2012.07.004.
878-5409/$ – see front matter © 2012 Japanese College of Cardiology. Published by Else
ttp://dx.doi.org/10.1016/j.jccase.2012.09.006of two  or more dysfunctional ion channels results in the loss of
repolarization reserve [13] and unmasks the prolongation of the
repolarization phase.
Although the incidence of compound mutations is more fre-
quent than that of expected theoretically, it is rare to diagnose
patients with compound mutations in daily clinical practice. But
two or more dysfunctioning ion channels frequently occur in
elderly patients with long QT syndrome. Elderly patients have many
chances to take drugs for various diseases. Mineral abnormalities,
especially hypokalemia, can frequently occur from gastrointestinal,
renal, or nutritional disorders. Drugs that prolong QT interval usu-
ally block IKr current and hypokalemia blocks both IKr and IK1; the
combination of these reduces the repolarization reserve. Existence
of organic heart disease, heart failure, and bradycardia also alter
the ion channel functions and prolong QT interval. In patients with
congenital long QT syndrome, young patients often experience syn-
cope or TdP by adrenergic stimulation (such as exercise and loud
noise), but adrenergic stimulation as proarrhythmic triggers is less
frequent in elderly patients. TdP often occurs by secondary triggers
as hypokalemia, bradycardia, and drugs in elderly patients [14]. If
patients have a single mutation, acquired triggers add the second
ion channel dysfunction and eliminate repolarization reserve, then
promote TdP. Compound ion channel dysfunctions can frequently
occur in elderly patients with long QT syndrome.
In patients without mutations, compound ion channel dysfunc-
tions can cause acquired long QT syndrome. Predisposing factors
for acquired QT prolongation are female gender, age, drugs, mineral
abnormalities, organic heart disease, arrhythmias, severe visceral
dysfunction, and QT prolongation at baseline. Accumulation of
predisposing factors markedly reduces repolarization reserve and
increases the incidence of cardiac events [15]. Indeed, patients
with syncope/TdP have more multiple predisposing factors at the
time of QT prolongation than do asymptomatic patients. Patients
with acquired long QT syndrome have complex T wave resembling
electrocardiograms in animal models of compound ion channel
dysfunction [9,10] and in patients with compound mutations. Com-
pound mutations in patients result in a rare severe form of long QT
syndrome, but it will be a clinical model of acquired long QT syn-
drome or elderly patients with a single mutation and secondary
trigger.
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